Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Abstract

Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the “ Complementary Exposure ” pattern: the targets of the drugs both hit the HCoV–host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.

Cited by papers we hold 25

• Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics · 2021
  Not checked
• SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals · 2021
  No notice
• Prediction of Synergistic Drug Combinations for Prostate Cancer by Transcriptomic and Network Characteristics · 2021
  Not checked
• De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning · 2021
  Not checked
• Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro · 2021
  No notice
• COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention · 2021
  No notice
• Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2 · 2021
  No notice
• An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 · 2021
  No notice
• Modulation of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in receptor, innate immunity and drug antiviral candidate · 2020
  Not checked
• Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection · 2020
  No notice
• The COVID-19 pandemic: a global health crisis · 2020
  No notice
• Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past · 2020
  No notice
• Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations · 2020
  No notice
• A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19 · 2020
  No notice
• Regulatory Cross Talk Between SARS-CoV-2 Receptor Binding and Replication Machinery in the Human Host · 2020
  Not checked
• Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention · 2020
  No notice
• A Review of SARS-CoV-2 and the Ongoing Clinical Trials · 2020
  No notice
• Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2 · 2020
  No notice
• Is Melatonin the Cornucopia of the 21st Century? · 2020
  No notice
• SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions · 2020
  No notice

and 5 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.